Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors

European Journal of Medicinal Chemistry

Volumn 46, Issue 7, 2011, Pages 2617-2629

  Nuti, Elisa ^a   Casalini, Francesca ^a   Santamaria, Salvatore ^a,d   Gabelloni, Pamela ^a   Bendinelli, Sara ^a   Da Pozzo, Eleonora ^a   Costa, Barbara ^a   Marinelli, Luciana ^b   La Pietra, Valeria ^b   Novellino, Ettore ^b   Margarida Bernardo, M ^c   Fridman, Rafael ^c   Da Settimo, Federico ^a   Martini, Claudia ^a   Rossello, Armando ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Anti glioma agents; Hydroxamic acids; Matrix metalloproteinase inhibitors; MMP 2; MMP 25; MMP 9

Indexed keywords

2 [5 [(4 BUTYLPHENYL)ETHYNYL]THIOPHENE 2 SULFONAMIDO) N HYDROXYACETAMIDE; 2 [5 [(4 BUTYLPHENYL)ETHYNYL]THIOPHENE 2 SULFONAMIDO] N HYDROXY 3 (1H INDOL 3 YL)PROPANAMIDE; 2 [5 [(4 BUTYLPHENYL)ETHYNYL]THIOPHENE 2 YLSULFONYL] N HYDROXY 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXAMIDE; 3 [4 (BENZYLOXY)PHENYL] 2 [5 [(4 BUTYLPHENYL)ETHYNYL]THIOPHENE 2 SULFONAMIDO] N HYDROXYPROPANAMIDE; 3 [4 BENZOYLPHENYL] 2 [5 [(4 BUTYLPHENYL)ETHYNYL]THIOPHENE 2 SULFONAMIDO] N HYDROXYPROPANAMIDE; 3 [5 [(4 BUTYLPHENYL)ETHYNYL]THIOPHEN 2 YLSULFONYL] N HYDROXYTHIAZOLIDINE 4 CARBOXAMIDE; 3 BENZO[B]THIOPHEN 3 YL) 2 [5 [(4 BUTYLPHENYL)ETHYNYL]THIOPHENE 2 SULFONAMIDO] N HYDROXYPROPANAMIDE; 4 BUTYLPHENYL(ETHYNYLTHIOPHENE)SULFONAMIDO HYDROXAMATE DERIVATIVE; ANTINEOPLASTIC AGENT; ETHYNYLTHIOPHENE; GELATINASE A; GELATINASE B; HYDROXAMIC ACID DERIVATIVE; INTERSTITIAL COLLAGENASE; MATRIGEL; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 25; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; STROMELYSIN; UNCLASSIFIED DRUG; COLLAGEN; DRUG COMBINATION; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HYDROXAMIC ACID; LAMININ; PROTEOGLYCAN; SULFONAMIDE; THIOPHENE DERIVATIVE;

ARTICLE; CANCER GROWTH; CELL GROWTH; CELL INVASION; CELL VIABILITY; DISEASE COURSE; DRUG ACTIVITY; ENZYME INHIBITION; GLIOBLASTOMA; GLIOMA CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; SYNTHESIS; CELL MOTION; CELL SURVIVAL; CHEMISTRY; DIFFUSION CHAMBER; DRUG COMBINATION; DRUG EFFECTS; ENZYMOLOGY; GLIA; METABOLISM; MOLECULAR DOCKING; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; COLLAGEN; DIFFUSION CHAMBERS, CULTURE; DRUG COMBINATIONS; GPI-LINKED PROTEINS; HUMANS; HYDROXAMIC ACIDS; LAMININ; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; MOLECULAR DOCKING SIMULATION; NEUROGLIA; PROTEOGLYCANS; SULFONAMIDES; THIOPHENES;

EID: 79957505622     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.03.033     Document Type: Article

References (65)

1. I. Koutroulis, A. Zarros, and S. Theocharis The role of matrix metalloproteinases in the pathophysiology and progression of human nervous system malignancies: a chance for the development of targeted therapeutic approaches? Expert Opin. Ther. Targets 12 2008 1577 1586
2. M.W. Roomi, J.C. Monterrey, T. Kalinovsky, M. Rath, and A. Niedzwiecki Patterns of MMP-2 and MMP-9 expression in human cancer cell lines Oncol. Rep. 21 2009 1323 1333
3. J.S. Rao Molecular mechanisms of glioma invasiveness: the role of proteases Nat. Rev. Cancer 3 2003 489 501 (Pubitemid 37328837)
4. O. Kargiotis, C. Chetty, C.S. Gondi, A.J. Tsung, D.H. Dinh, M. Gujrati, S.S. Lakka, A.P. Kyritsis, and J.S. Rao Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma Oncogene 27 2008 4830 4840
5. P.A. Forsyth, H. Wong, T.D. Laing, N.B. Rewcastle, D.G. Morris, H. Muzik, K.J. Leco, R.N. Johnston, P.M. Brasher, G. Sutherland, and D.R. Edwards Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas Br. J. Cancer 79 1999 1828 1835 (Pubitemid 29132312)
6. K. Komatsu, Y. Nakanishi, N. Nemoto, T. Hori, T. Sawada, and M. Kobayashi Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas Brain Tumor Pathol. 21 2004 105 112 (Pubitemid 40187984)
7. L.M. Coussens, B. Fingleton, and L.M. Matrisian Matrix metalloproteinase inhibitors and cancer: trials and tribulations Science 295 2002 2387 2392 (Pubitemid 34270240)
8. R.P. Beckett, A.H. Davidson, A.H. Drummond, P. Huxley, and M. Whittaker Recent advances in matrix metalloproteinase inhibitor research Drug Discov. Today 1 1996 16 26 (Pubitemid 126402598)
9. V.A. Levin, S. Phuohanic, W.K.A. Yung, P.A. Forsyth, R. Del Maestro, R.J. Perry, G.N. Fuller, and M. Baillet Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation J. Neurooncol. 78 2006 295 302 (Pubitemid 44018824)
10. L.A. Sorbera, and J. Castaner Prinomastat: oncolytic, matrix metalloproteinase inhibitor Drugs Fut. 25 2000 150 158 (Pubitemid 30182773)
11. N.C. Levitt, F.A. Eskens, K.J. O'Byrne, D.J. Propper, L.J. Denis, S.J. Owen, L. Choi, J.A. Foekens, S. Wilner, J.M. Wood, M. Nakajima, D.C. Talbot, W.P. Steward, A.L. Harris, and J. Verweij Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer Clin. Cancer Res. 7 2001 1912 1922 (Pubitemid 32994825)
12. P.A. Konstantinopoulos, M.V. Karamouzis, A.G. Papatsoris, and A.G. Papavassiliou Matrix metalloproteinase inhibitors as anticancer agents Int. J. Biochem. Cell. Biol. 40 2008 1156 1168
13. C.M. Overall, and O. Kleifeld Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy Nat. Rev. Cancer 6 2006 227 239 (Pubitemid 43292566)
14. D.P. Becker, T.E. Barta, L.J. Bedell, T.L. Boehm, B.R. Bond, J. Carroll, C.P. Carron, G.A. Decrescenzo, A.M. Easton, J.N. Freskos, C.L. Funckes-Shippy, M. Heron, S. Hockerman, C.P. Howard, J.R. Kiefer, M.H. Li, K.J. Mathis, J.J. McDonald, P.P. Mehta, G.E. Munie, T. Sunyer, C.A. Swearingen, C.I. Villamil, D. Welsch, J.M. Williams, Y. Yu, and J. Yao Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease J. Med. Chem. 53 2010 6653 6680
15. C. López-Otín, L.H. Palavalli, and Y. Samuels Protective roles of matrix metalloproteinases: from mouse models to human cancer Cell Cycle 8 2009 3657 3662
16. D.T. Puerta, J. Mongan, B.L. Tran, J.A. McCammon, and S.M. Cohen Potent, selective pyrone-based inhibitors of stromelysin-1 J. Am. Chem. Soc. 127 2005 14148 14149 (Pubitemid 41457556)
17. D.T. Puerta, M.O. Griffin, J.A. Lewis, D. Romero-Perez, R. Garcia, F.J. Villarreal, and S.M. Cohen Heterocyclic zinc-binding groups for use in next-generation matrix metalloproteinase inhibitors: potency, toxicity, and reactivity J. Biol. Inorg. Chem. 11 2006 131 138 (Pubitemid 43228206)
18. Regarding the debate on the use of hydroxamates as ZBG for metalloenzymes see:
19. E. Nuti, L. Panelli, F. Casalini, S.I. Avramova, E. Orlandini, S. Santamaria, S. Nencetti, T. Tuccinardi, A. Martinelli, G. Cercignani, N. D'Amelio, A. Maiocchi, F. Uggeri, and A. Rossello Design, synthesis, biological evaluation and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors J. Med. Chem. 52 2009 6347 6361
20. M. Flipo, J. Charton, A. Hocine, S. Dassonneville, B. Deprez, and R. Deprez-Poulain Hydroxamates: relationships between structure and plasma stability J. Med. Chem. 52 2009 6790 6802
21. Y. Tamura, F. Watanabe, T. Nakatani, K. Yasui, M. Fuji, T. Komurasaki, H. Tsuzuki, R. Maekawa, T. Yoshioka, K. Kawada, K. Sugita, and M. Ohtani Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives J. Med. Chem. 41 1998 640 649 (Pubitemid 28093097)
22. R. Kiyama, Y. Tamura, F. Watanabe, H. Tsuzuki, M. Ohtani, and M. Yodo Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors J. Med. Chem. 42 1999 1723 1738 (Pubitemid 29244966)
23. G.E. Terp, G. Cruciani, I.T. Christensen, and F.S. Jorgensen Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach J. Med. Chem. 45 2002 2675 2684 (Pubitemid 34627640)
24. L. Aureli, M. Gioia, I. Cerbara, S. Monaco, G.F. Fasciglione, S. Marini, P. Ascenzi, A. Topai, and M. Coletta Structural bases for substrate and inhibitor recognition by matrix metalloproteinases Curr. Med. Chem. 15 2008 2192 2222
25. A. Agrawal, D. Romero-Perez, J.A. Jacobsen, F.J. Villarreal, and S.M. Cohen Zinc-binding groups modulate selective inhibition of MMPs Chem. Med. Chem. 3 2008 812 820
26. A. Rossello, E. Nuti, P. Carelli, E. Orlandini, M. Macchia, S. Nencetti, M. Zandomeneghi, F. Balzano, G. Uccello Barretta, A. Albini, R. Benelli, G. Cercignani, G. Murphy, and A. Balsamo N-i-propoxy-N- biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP Bioorg. Med. Chem. Lett. 15 2005 1321 1326 (Pubitemid 40268984)
27. S. Hanessian, D.B. MacKay, and N. Moitessier Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors J. Med. Chem. 44 2001 3074 3082 (Pubitemid 32862338)
28. B.R. Neustadt Facile preparation of N-(sulfonyl)carbamates Tetrahedron Lett. 35 1994 379 380 (Pubitemid 24051188)
29. K. Sonogashira, Y. Tohda, and N. Hagihara Convenient synthesis of acetylenes: catalytic substitutions of acetylenic hydrogen with bromoalkenes, iodoarenes, and bromopyridines Tetrahedron Lett. 50 1975 4467 4470
30. E. Shirakawa, T. Sato, Y. Imazaki, T. Kimura, and T. Hayashi Cobalt-catalyzed cross-coupling of alkynyl Grignard reagents with alkenyl triflates Chem. Commun. 43 2007 4513 4515 (Pubitemid 350045950)
31. E. Nuti, E. Orlandini, S. Nencetti, A. Rossello, A. Innocenti, A. Scozzafava, and C.T. Supuran Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates Bioorg. Med. Chem. 15 2007 2298 2311 (Pubitemid 46242198)
32. D.P. Becker, C.I. Villamil, T.E. Barta, L.J. Bedell, T.L. Boehm, G.A. Decrescenzo, J.N. Freskos, D.P. Getman, S. Hockerman, R. Heintz, S.C. Howard, M.H. Li, J.J. McDonald, C.P. Carron, C.L. Funckes-Shippy, P.P. Mehta, G.E. Munie, and C.A. Swearingen Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy J. Med. Chem. 48 2005 6713 6730 (Pubitemid 41504727)
33. S.L. Zheng, S. Reid, N. Lin, and B. Wang Microwave-assisted synthesis of ethynylarylboronates for the construction of boronic acid-based fluorescent sensors for carbohydrates Tetrahedron Lett. 47 2006 2331 2335 (Pubitemid 43361668)
34. B.C. Shook, D. Chakravarty, and P.F. Jackson Microwave-assisted Sonogashira-type cross couplings of various heterocyclic methylthioethers Tetrahedron Lett. 50 2009 1013 1015
35. 2, a fluorogenic substrate with increased specificity constants for collagenases and tumor necrosis factor converting enzyme Anal. Biochem. 328 2004 166 173 (Pubitemid 38542933)
36. V. Dhanaraj, M.G. Williams, Q.-Z. Ye, F. Molina, L.L. Johnson, D.F. Ortwine, A. Pavlovsky, J.R. Rubin, R.W. Skeean, A.D. White, C. Humblet, D.J. Hupe, and T.L. Blundell X-ray structure of gelatinase A catalytic domain complexed with a hydroxamate inhibitor Croat. Chem. Acta 72 1999 575 591
37. D. Pei Leukolysin/MMP25/MT6-MMP: a novel matrix metalloproteinase specifically expressed in the leukocyte lineage Cell Res. 9 1999 291 303 (Pubitemid 129623934)
38. Q. Sun, C.R. Weber, A. Sohail, M.M. Bernardo, M. Toth, H. Zhao, J.R. Turner, and R. Fridman MMP25 (MT6-MMP) is highly expressed in human colon cancer, promotes tumor growth, and exhibits unique biochemical properties J. Biol. Chem. 282 2007 21998 22010 (Pubitemid 47195749)
39. G. Velasco, S. Cal, A. Merlos-Suárez, A.A. Ferrando, S. Alvarez, A. Nakano, J. Arribas, and C. López-Otín Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors Cancer Res. 60 2000 877 882 (Pubitemid 30129519)
40. R.K. Nuttall, C.J. Pennington, J. Taplin, A. Wheal, V.W. Yong, P.A. Forsyth, and D.R. Edwards Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells Mol. Cancer Res. 1 2003 333 345 (Pubitemid 36437920)
41. A. Sohail, Q. Sun, H. Zhao, M.M. Bernardo, J.A. Cho, and R. Fridman A unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer Cancer Metastasis Rev. 27 2008 289 302
42. A. Krüger, M.J. Arlt, M. Gerg, C. Kopitz, M.M. Bernardo, M. Chang, S. Mobashery, and R. Fridman Antimetastatic activity of a novel mechanism-based gelatinase inhibitor Cancer Res. 65 2005 3523 3526 (Pubitemid 40616323)
43. R.D. Bonfil, A. Sabbota, S. Nabha, M.M. Bernardo, Z. Dong, H. Meng, H. Yamamoto, S.R. Chinni, I.T. Lim, M. Chang, L.C. Filetti, S. Mobashery, M.L. Cher, and R. Fridman Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor Int. J. Cancer 118 2006 2721 2726 (Pubitemid 43673349)
44. A. Hoffman, B. Qadri, J. Frant, Y. Katz, S.R. Bhusare, E. Breuer, R. Hadar, and R. Reich Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor - synthesis and pharmacodynamic and pharmacokinetic analysis J. Med. Chem. 51 2008 1406 1414 (Pubitemid 351480402)
45. M. Lee, G. Celenza, B. Boggess, J. Blase, Q. Shi, M. Toth, M.M. Bernardo, W.R. Wolter, M.A. Suckow, D. Hesek, B.C. Noll, R. Fridman, S. Mobashery, and M. Chang A potent gelatinase inhibitor with anti-tumor-invasive activity and its metabolic disposition Chem. Biol. Drug Des. 73 2009 189 202
46. P. Gabelloni, E. Da Pozzo, S. Bendinelli, B. Costa, E. Nuti, F. Casalini, E. Orlandini, F. Da Settimo, A. Rossello, and C. Martini Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma Neuroscience 168 2010 514 522
47. L.J. MacPherson, E.K. Bayburt, M.P. Capparelli, B.J. Carroll, R. Goldstein, M.R. Justice, L. Zhu, S. Hu, R.A. Melton, L. Fryer, R.L. Goldberg, J.R. Doughty, S. Spirito, V. Blancuzzi, D. Wilson, E.M. O'Byrne, V. Ganu, and D.T. Parker Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits J. Med. Chem. 40 1997 2525 2532 (Pubitemid 27347016)
48. C.G. Knight, F. Willenbrock, and G. Murphy A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases FEBS Lett. 296 1992 263 266
49. SoftMax Pro 4.7.1 by Molecular Devices.
50. GraFit version 4 by Erithecus Software.
51. Glide, Version 5.5 2009 Schrödinger, LLC New York, NY
52. Maestro, Version 9.0.211 2009 Schrodinger, L.L.C. New York, NY
53. E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, and T.E. Ferrin UCSF chimera - a visualization system for exploratory research and analysis J. Comput. Chem. 25 2004 1605 1612
54. A.W. Schuttelkopf, and D.M. van Aalten PRODRG: a tool for high-throughput crystallography of protein-ligand complexes Acta Crystallogr. Sect. D Biol. Crystallogr. 60 2004 1355 1363 (Pubitemid 41079731)
55. J.W. Storer, D.J. Giesen, C.J. Cramer, and D.G. Truhlar Class IV charge models: a new semiempirical approach in quantum chemistry J. Comput-Aided Mol. Des 9 1995 87 110
56. J.D. Thompson, C.J. Cramer, and D.G. Truhlar Parameterization of charge model 3 for AM1, PM3, BLYP, and B3LYP J. Comput. Chem. 24 2003 1291 1304
57. W.L. Jorgensen, D.S. Maxwell, and J. Tirado-Rives Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids J. Am. Chem. Soc. 118 1996 11225 11236 (Pubitemid 26399746)
58. W.L.B.O.S.S. Jorgensen Version 4.6 2004 Yale University New Haven, CT
59. M. Udier-Blagović, P. Morales De Tirado, S.A. Pearlman, and W.L. Jorgensen Accuracy of free energies of hydration using CM1 and CM3 atomic charges J. Comput. Chem. 25 2004 1322 1332
60. R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, M.P. Repasky, E.H. Knoll, M. Shelley, J.K. Perry, D.E. Shaw, P. Francis, and P.S. Shenkin Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 47 2004 1739 1749 (Pubitemid 38380917)
61. R.A. Friesner, R.B. Murphy, M.P. Repasky, L.L. Frye, J.R. Greenwood, T.A. Halgren, P.C. Sanschagrin, and D.T. Mainz Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes J. Med. Chem. 49 2006 6177 6196 (Pubitemid 44595196)
62. S. Ruan, M.F. Okcu, R.C. Pong, M. Andreeff, V. Levin, J.T. Hsieh, and W. Zhang Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin Clin. Cancer Res. 5 1999 197 202 (Pubitemid 29045194)
63. ImageJ Software, version 1.41o, USA.
64. GraphPad Software, version 4.0, San Diego, CA.
65. MicroMath Scientific Software, Salt Lake City, UT.